In the current study we utilized both colorectal cancer cell lines and PDTX models to demonstrate that PI3K/MEK combination therapy is more active than single agent treatment in models of CRC with distinct molecular backgrounds. This evidence concerns the gene MAP2K7 and colorectal cancer.